Insight on AI – May 2026, Issue 12
Welcome to the May, Issue 12 edition of Artificial Vigilance, Essjay Solutions, Insight on AI, dedicated to helping pharmacovigilance professionals understand, engage with and adapt to the rapidly evolving world of artificial intelligence.
Innovation
Social Media: The Newest Frontier for Pharmacovigilance
Social media is emerging as a valuable supplementary source of pharmacovigilance data, offering access to patient experiences that may never appear in traditional adverse event reporting systems. Advances in natural language processing now allow AI systems to analyse large volumes of online conversations, identify symptom patterns and detect potential safety signals in near real time. Research analysing hundreds of thousands of social media posts related to medicines such as semaglutide and tirzepatide has uncovered patient-reported experiences that are often absent from structured clinical datasets. Despite challenges around data quality, validation, misinformation and bot activity, social media monitoring reflects a broader shift toward continuous, real-world safety surveillance powered by AI, digital health technologies and increasingly connected patient data streams.
AI News
The Real Danger of Healthcare AI is not Hallucination; It’s How it Affects Your Thinking
While discussions about healthcare AI often focus on hallucinations, bias and reliability, researchers are increasingly concerned about AI’s influence on human reasoning itself. Research from Archie Cotterill at Maidstone and Tunbridge Wells NHS Trust suggests that generative AI does more than provide information; it frames problems before clinicians begin their own analysis, subtly shaping which possibilities are considered and which are overlooked. Studies have shown clinicians frequently alter decisions after consulting AI systems, even when outputs are incorrect, raising concerns that overreliance on AI could weaken independent clinical judgement over time. As healthcare organisations accelerate AI adoption, preserving critical thinking and clinical expertise may become just as important as addressing technical limitations such as hallucinations.
Industry
Parexel Acquires Vitrana to Boost Drug Safety Automation
Parexel’s acquisition of AI safety technology firm Vitrana reflects the growing importance of automation in pharmacovigilance. Vitrana’s platform automates key safety processes including case intake, data extraction, entity mapping, reconciliation and narrative generation, helping organisations manage increasing volumes of adverse event data while maintaining regulatory oversight. Early deployments have reportedly reduced case processing times by 60% and manual reconciliation efforts by 75%, highlighting the potential for AI to improve efficiency across safety operations. The acquisition also aligns with Parexel’s broader strategy of investing in AI-powered regulatory, clinical and safety infrastructure, while reinforcing the need for strong governance, traceability and scientific oversight as automation becomes more deeply embedded within pharmacovigilance workflows.
Regulation
AI Governance is Becoming Pharma’s Next Big Compliance Challenge
As generative AI becomes increasingly integrated into GxP environments, regulators are placing greater emphasis on validation, explainability, accountability and oversight. Growing scrutiny from regulators, alongside frameworks such as the EU AI Act, is driving pharmaceutical organisations to develop more robust governance structures for AI deployment. Recent regulatory findings have reinforced that while AI can support regulated processes, responsibility remains with the organisations using these systems. In response, new executive training programmes focused on decision-grade AI governance are emerging to help industry leaders manage AI safely within regulated environments. The organisations most likely to succeed with AI may not be those deploying the most advanced models, but those capable of demonstrating validation, auditability and effective governance of AI-generated outputs.
